Australia markets open in 6 hours 54 minutes

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.64+0.09 (+1.05%)
As of 01:05PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close8.55
Open8.72
Bid8.61 x 800
Ask8.63 x 900
Day's range8.60 - 8.95
52-week range2.60 - 9.84
Volume232,412
Avg. volume777,446
Market cap922.268M
Beta (5Y monthly)-0.49
PE ratio (TTM)N/A
EPS (TTM)-0.90
Earnings date09 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.03
  • Business Wire

    BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights

    LAVAL, Quebec, May 11, 2022--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today reported its financial and operating results for the first quarter ending March 31, 2022.

  • Business Wire

    BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

    LAVAL, Quebec, May 02, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference, being held in San

  • Business Wire

    BELLUS Health to Participate in Multiple Upcoming Investor Conferences

    LAVAL, Quebec, April 25, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that the Company’s management team will participate in multiple upcoming investor conferences.